Slides and webcasts from ESMO Virtual Plenaries are open to all ESMO Account holders, according to the presenters' agreement to release them.
Login and Watch now!
ESMO Virtual Plenary: July 2022
- Start date
- 14 Jul 2022
- End date
- 15 Jul 2022
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.
The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.
Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up
Thursday, 14 July 2022 |
Friday, 15 July 2022 |
|---|---|
18:30-19:30 CEST |
13:00-14:10 CEST / 19:00-20:10 SGT |
Programme
Welcome and introduction, Scientific background and context Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up Sibylle Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany Critical analysis and perspectives Discussion and Q&A (i) Faculty and online audience |
Programme
Virtual Plenary Expert Insights: Webcast of 14 July presentations, Discussion and Q&A (ii) Chair: Elaine Lim Hsuen, NCCS - National Cancer Centre Singapore, Singapore Sibylle Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany Javier Cortés, International Breast Cancer Center, IBCC, Barcelona, Spain Sung-Bae Kim, Asan Medical Center - University of Ulsan, Seoul, Republic of Korea Mastura MD Yusof, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia |
